Aziz

List of Publications by Year in Descending Order

196 papers	2,310 citations	24 h-index	44 g-index
200 ext. papers	3,015 ext. citations	3.5 avg, IF	4.9 L-index

#	Paper	IF	Citations
196	Simplified Pediatric Index of Mortality 3 Score by Explainable Machine Learning Algorithm **2021**, 3, e0561		0
195	Should I rock the boat? When to stop TKIs in CML. *Blood*, **2021**, 137, 1136-1137	2.2	
194	Novel Machine Learning Can Predict Acute Asthma Exacerbation. *Chest*, **2021**, 159, 1747-1757	5.3	9
193	What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?. *Leukemia and Lymphoma*, **2021**, 62, 2762-2767	1.9	1
192	Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia. *Blood*, **2021**, 138, 1885-1895	2.2	3
191	Analysis of distinct hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. *Leukemia and Lymphoma*, **2021**, 62, 735-738	1.9	2
190	Prognostic impact of serum CXC chemokine ligands 4 and 7 on myelodysplastic syndromes post allogeneic hematopoietic cell transplant. *Leukemia and Lymphoma*, **2021**, 62, 229-233	1.9	
189	What is machine learning?. *Archives of Disease in Childhood: Education and Practice Edition*, **2021**,	0.5	1
188	Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia. *Transplantation and Cellular Therapy*, **2021**, 27, 917.e1-917.e9		0
187	Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. *Journal of Clinical Oncology*, **2021**, 39, 3737-3746	2.2	14
186	Personalized Prediction of Hospital Mortality in COVID-19-Positive Patients. *Mayo Clinic Proceedings Innovations, Quality & Outcomes*, **2021**, 5, 795-801	3.1	2
185	Impact of Epigenomic Hypermethylation at TP53 on Allogeneic Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndromes. *Transplantation and Cellular Therapy*, **2021**, 27, 659.e1-659.e6		1
184	A geno-clinical decision model for the diagnosis of myelodysplastic syndromes. *Blood Advances*, **2021**, 5, 4361-4369	7.8	2
183	Acute myeloid leukemia and artificial intelligence, algorithms and new scores. *Best Practice and Research in Clinical Haematology*, **2020**, 33, 101192	4.2	6
182	Machine learning in haematological malignancies. *Lancet Haematology,the*, **2020**, 7, e541-e550	14.6	31
181	Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantation. *British Journal of Haematology*, **2020**, 189, 318-322	4.5	3
180	Artificial Intelligence in Hematology: Current Challenges and Opportunities. *Current Hematologic Malignancy Reports*, **2020**, 15, 203-210	4.4	10

179	Personalized predictions of patient outcomes during and after hospitalization using artificial intelligence. *Npj Digital Medicine*, **2020**, 3, 51	15.7	14
178	Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes. *Leukemia and Lymphoma*, **2020**, 61, 1943-1953	1.9	1
177	The Genomic Landscape of Wilms Tumor 1 (WT1) Mutant Acute Myeloid Leukemia. *Blood*, **2020**, 136, 28-28	2.2	
176	A Phase I/II Trial of CPX-351 + Palbociclib in Patients with Acute Myeloid Leukemia. *Blood*, **2020**, 136, 13-14	2.2	1
175	TET2 Inhibitory Effects of Eltrombopag Contribute Its Hematopoietic Activity. *Blood*, **2020**, 136, 2-3	2.2	
174	A Phase II Study of CPX-351 As a Novel Therapeutic Approach for Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent Failure. *Blood*, **2020**, 136, 1-1	2.2	1
173	The Evolving Landscape of Myelodysplastic Syndrome Prognostication. *Clinical Hematology International*, **2020**, 2, 43-48	1.8	4
172	Molecular dissection of normal karyotype acute myeloid leukemia.. *Journal of Clinical Oncology*, **2020**, 38, 7534-7534	2.2	
171	A personalized prediction model for hospital readmission risk for cancer patients.. *Journal of Clinical Oncology*, **2020**, 38, 7057-7057	2.2	
170	Genomics of therapy-related myeloid neoplasms. *Haematologica*, **2020**, 105, e98-e101	6.6	10
169	Novel Prognostic Models for Myelodysplastic Syndromes. *Hematology/Oncology Clinics of North America*, **2020**, 34, 369-378	3.1	3
168	Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes. *Blood*, **2020**, 136, 2249-2262	2.2	21
167	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. *Lancet Haematology,the*, **2020**, 7, e601-e612	14.6	41
166	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 2139-2146	4.7	6
165	Revised 15-item MDS-specific frailty scale maintains prognostic potential. *Leukemia*, **2020**, 34, 3434-3438	10.7	5
164	Machine Learning in Oncology: What Should Clinicians Know?. *JCO Clinical Cancer Informatics*, **2020**, 4, 799-810	5.2	17
163	Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia. *Communications Biology*, **2020**, 3, 493	6.7	13
162	Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome. *Leukemia*, **2020**, 34, 957-962	10.7	16

161	Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence. *JCO Precision Oncology*, **2019**, 3,	3.6	11
160	A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia. *Clinical Cancer Research*, **2019**, 25, 4231-4237	12.9	19
159	Impact of germline CTC1 alterations on telomere length in acquired bone marrow failure. *British Journal of Haematology*, **2019**, 185, 935-939	4.5	5
158	Timing for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myelomonocytic Leukemia (CMML): A Joint Study from the International MDS/MPN Working Group and the Chronic Malignancies Working Party of the EBMT. *Blood*, **2019**, 134, 4581-4581	2.2	2
157	RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia. *Blood*, **2019**, 134, 2696-2696	2.2	1
156	Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms. *Blood*, **2019**, 134, 4238-4238	2.2	2
155	Epigenomic Signatures in Myelodysplastic Syndrome Patients As Predictors of Donor Compatibility and Transplant Outcome. *Blood*, **2019**, 134, 4557-4557	2.2	1
154	How Morphologic Features Are Shaped By Underlying Somatic Genotype in MDS. *Blood*, **2019**, 134, 1716-1716	2.2	1
153	A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML) Using Artificial Intelligence. *Blood*, **2019**, 134, 2091-2091	2.2	8
152	Can Monosomy 7 be Targeted By Next Generation Cereblon-Modulating Agents?. *Blood*, **2019**, 134, 1270-1270	2.2	0
151	FA Gene Carrier Status Predisposes to Myeloid Neoplasms and Bone Marrow Failure in Adults. *Blood*, **2019**, 134, 452-452	2.2	2
150	The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy. *Blood*, **2019**, 134, 16-16	2.2	2
149	Pattern of Somatic Mutation Changes from Diagnosis to Relapse Following Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). *Blood*, **2019**, 134, 2716-2716	2.2	2
148	Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS). *Blood*, **2019**, 134, 678-678	2.2	19
147	Impact and Outcomes of RAS gene Mutations in Core Binding Factor Acute Myeloid Leukemia. *Blood*, **2019**, 134, 2720-2720	2.2	2
146	Mutational Patterns and Clonal Architecture of Therapy-Related Acute Myeloid Leukemia. *Blood*, **2019**, 134, 1405-1405	2.2	1
145	Advances in Acute Myeloid Leukemia Genomics, Where Do We Stand in 2018?. *Acta Medica Academica*, **2019**, 48, 35-44	0.8	3
144	Towards Molecularly Informed Acute Myeloid Leukemia Subtyping Reflective of Pathogenesis. *Blood*, **2019**, 134, 1406-1406	2.2	

143	Molecular Dissection of Del(5q): Distinction between Primary and Secondary Del(5q) and Pathogenetic Implications. *Blood*, **2019**, 134, 4221-4221	2.2	
142	The Biological Inferences from the Ranking of SF3B1 Mutations in the Clonal Hierarchy of Myeloid Neoplasia. *Blood*, **2019**, 134, 5411-5411	2.2	
141	Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features. *Blood*, **2019**, 134, 2992-2992	2.2	
140	Identifying Factors That Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine Based Therapies. *Blood*, **2019**, 134, 3433-3433	2.2	
139	ANKRD26 Coding Variants Presenting with Giant Platelets and a Predisposition to Myeloid Neoplasia. *Blood*, **2019**, 134, 4233-4233	2.2	
138	Large Granular Lymphocytic Leukemia Coexists with Clonal Hematopoiesis of Indeterminate Potential. *Blood*, **2019**, 134, 3743-3743	2.2	
137	Are Racial Disparities in Acute Myeloid Leukemia (AML) Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?. *Blood*, **2019**, 134, 381-381	2.2	0
136	First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia. *Blood*, **2019**, 134, 3920-3920	2.2	0
135	Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI). *Blood*, **2019**, 134, 2089-2089	2.2	
134	Interactions between Donor Activating Killer Immunoglobulin-like Receptors (KIRs) and Somatic Mutations and Their Association with Outcomes after Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia (AML). *Blood*, **2019**, 134, 4599-4599	2.2	
133	Hotspot U2AF1 Mutations Determine Missplicing Selectivity: Novel Mechanisms Altering Splicing Factors. *Blood*, **2019**, 134, 2985-2985	2.2	0
132	SEL120 - a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial. *Blood*, **2019**, 134, 2651-2651	2.2	1
131	A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy. *Blood*, **2019**, 134, 2595-2595	2.2	
130	Determinants of "Fitness" for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients. *Blood*, **2019**, 134, 3836-3836	2.2	
129	Invariant phenotype and molecular association of biallelic mutant myeloid neoplasia. *Blood Advances*, **2019**, 3, 339-349	7.8	18
128	Distinct clinical and biological implications of in myeloid neoplasms. *Blood Advances*, **2019**, 3, 2164-2178	7.8	12
127	Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. *Blood Advances*, **2019**, 3, 4228-4237	7.8	16
126	Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes. *Nature Communications*, **2019**, 10, 5386	17.4	29

125	Does mutational burden add to other prognostic factors in MDS?. *Best Practice and Research in Clinical Haematology*, **2019**, 32, 101098	4.2	2
124	Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes. *Bone Marrow Transplantation*, **2019**, 54, 1281-1286	4.4	17
123	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. *Leukemia*, **2019**, 33, 1747-1758	10.7	88
122	and mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes. *Leukemia and Lymphoma*, **2019**, 60, 1587-1590	1.9	9
121	Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. *Blood Cancer Journal*, **2018**, 8, 4	7	21
120	Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL). *Leukemia and Lymphoma*, **2018**, 59, 416-422	1.9	42
119	Making Sense of Prognostic Models in Chronic Myelomonocytic Leukemia. *Current Hematologic Malignancy Reports*, **2018**, 13, 341-347	4.4	3
118	Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R. *American Journal of Hematology*, **2018**, 93, 1245-1253	7.1	18
117	Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes. *Blood*, **2018**, 132, 1797-1797	2.2	2
116	A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes. *Blood*, **2018**, 132, 793-793	2.2	18
115	What Is the Optimal Time to Initiate Hypomethylating Agents (HMA) in Higher Risk Myelodysplastic Syndromes (MDS)?. *Blood*, **2018**, 132, 3098-3098	2.2	3
114	Impact of Venous Thromboembolism during High Intensity Chemotherapy for Acute Leukemia Patients on Duration of Hospital Stay. *Blood*, **2018**, 132, 4806-4806	2.2	1
113	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes: On Behalf of the CIBMTR Chronic Leukemia Committee. *Blood*, **2018**, 132, 206-206	2.2	3
112	Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2mutations after Intensive Chemotherapy. *Blood*, **2018**, 132, 1389-1389	2.2	1
111	Somatic Mutations in Therapy-Related Myeloid Neoplasms Are Influenced By Therapeutic Modality and Clonal Hematopoiesis of Indeterminate Potential. *Blood*, **2018**, 132, 3084-3084	2.2	1
110	Invariant Patterns of Clonal Succession Determines Specific Phenotypic and Clinical Features of Myelodysplastic Syndromes (MDS). *Blood*, **2018**, 132, 104-104	2.2	
109	TP53 Mutations in Myeloid Neoplasm Patients with and without Significant Personal and Family History of Cancer. *Blood*, **2018**, 132, 2270-2270	2.2	
108	Molecular Characterization of Acute Myeloid Leukemia Patients with Normal Karyotype. *Blood*, **2018**, 132, 2809-2809	2.2	

107	Distinct Features of Chip-Derived and De Novo MDS. *Blood*, **2018**, 132, 2572-2572	2.2	
106	BRCA1 & BRCA2 Germline Variants Are Enriched in MDS/AML and Portend Higher Average Mutational Burden. *Blood*, **2018**, 132, 4352-4352	2.2	
105	Does Trial Participation Improve Outcomes for Higher-Risk Myelodysplastic Syndromes (MDS) Patients Treated at Specialty Centers?. *Blood*, **2018**, 132, 3096-3096	2.2	
104	Biallelic TET2 Inactivation in Myeloid Neoplasia: From Clonal Hierarchy to Clinical Phenotypes. *Blood*, **2018**, 132, 1805-1805	2.2	
103	Distinct Implications of TP53 Hits for Patients with Treatment-Related MDS and AML. *Blood*, **2018**, 132, 4353-4353	2.2	
102	Is There an Increased Risk of ALL in Patients with First Cancers Treated with Radiotherapy and/or Chemotherapy?. *Blood*, **2018**, 132, 900-900	2.2	
101	Modulation of TET2 Activity By Ascorbic Acid and Factors Affecting Lysine Acetylation. *Blood*, **2018**, 132, 4346-4346	2.2	
100	Molecular Spectrum of CSF3R variants Correlate with Specific Myeloid Malignancies and Secondary Mutations. *Blood*, **2018**, 132, 4389-4389	2.2	
99	Lessons from Nature: A Novel Class of TET Inhibitors for TET2 Mutant Associated Diseases. *Blood*, **2018**, 132, 4345-4345	2.2	0
98	Evaluating the Evidence for Long-Term Benefit from Specialty Centers Versus Real World for MDS Patients Treated with HMA. *Blood*, **2018**, 132, 3095-3095	2.2	
97	Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia. *Blood*, **2018**, 132, 2075-2075	2.2	
96	Analysis of Even a Limited Number of Genes Indicates a Strong Inherited Component in Otherwise Typical Sporadic MDS. *Blood*, **2018**, 132, 3074-3074	2.2	
95	Survival Outcomes of Patients with Therapy-Related Acute Myeloid Leukemia in the United States. *Blood*, **2018**, 132, 2298-2298	2.2	
94	Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia. *Blood*, **2018**, 132, 1527-1527	2.2	
93	Impact of Eltrombopag on Clonal Evolution in Refractory Aplastic Anemia. *Blood*, **2018**, 132, 3869-3869	2.2	
92	Risk of Venous Thromboembolism in Acute Leukemias: A Meta-Analysis. *Blood*, **2018**, 132, 4805-4805	2.2	
91	The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. *Blood Advances*, **2018**, 2, 1765-1772	7.8	63
90	Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer. *Journal of Clinical Oncology*, **2018**, 36, 1831-1839	2.2	67

89	Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. *Blood*, **2018**, 132, 2100-2103	2.2	26
88	Online and Social Media Resources for Patients with MDS. *Current Hematologic Malignancy Reports*, **2018**, 13, 570-575	4.4	
87	The MDS genomics-prognosis symbiosis. *Hematology American Society of Hematology Education Program*, **2018**, 2018, 270-276	3.1	12
86	Consequences of mutant TET2 on clonality and subclonal hierarchy. *Leukemia*, **2018**, 32, 1751-1761	10.7	30
85	Molecular features of early onset adult myelodysplastic syndrome. *Haematologica*, **2017**, 102, 1028-1034	6.6	13
84	Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells. *Nature Communications*, **2017**, 8, 15102	17.4	61
83	Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure. *Leukemia and Lymphoma*, **2017**, 58, 2532-2539	1.9	6
82	Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. *Journal of Clinical Oncology*, **2017**, 35, 2745-2753	2.2	154
81	Impact of social media for the hematologist/oncologist. *Seminars in Hematology*, **2017**, 54, 193-197	4	10
80	Origins of myelodysplastic syndromes after aplastic anemia. *Blood*, **2017**, 130, 1953-1957	2.2	32
79	Precision Medicine in Myelodysplastic Syndromes and Leukemias: Lessons from Sequential Mutations. *Annual Review of Medicine*, **2017**, 68, 127-137	17.4	5
78	Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS. *Current Hematologic Malignancy Reports*, **2017**, 12, 461-467	4.4	21
77	Extent and Clinical Implications of Subclonal Diversity in Paroxysmal Nocturnal Hemoglobinuria. *Blood*, **2017**, 130, 779-779	2.2	2
76	Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?. *Critical Reviews in Oncology/Hematology*, **2016**, 105, 112-7	7	9
75	The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. *Haematologica*, **2016**, 101, e224-7	6.6	30
74	Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?. *Oncologist*, **2016**, 21, 475-80	5.7	3
73	Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. *Leukemia Research*, **2016**, 41, 43-7	2.7	21
72	Molecular and Immunophenotypic Characteristics of Adult Acute Leukemias of Ambiguous Lineage. *Blood*, **2016**, 128, 1659-1659	2.2	1

71	PHF6 Somatic Mutations and Their Functional Role in the Pathophysiology of Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). *Blood*, **2016**, 128, 2736-2736	2.2	3
70	Forty-Year Analysis of Randomized Clinical Trials in Patients with Acute Myeloid Leukemia Treated with Remission Induction Chemotherapy. *Blood*, **2016**, 128, 2786-2786	2.2	2
69	U2AF1 Mutations in S34 and Q157 Create Distinct Molecular and Clinical Contexts. *Blood*, **2016**, 128, 3155-3155	2.2	1
68	Pathogenic Relevance of Germ Line TET2 Alterations. *Blood*, **2016**, 128, 3160-3160	2.2	1
67	Clonal Dynamics of Refractory Aplastic Anemia in Patients Treated with Eltrombopag. *Blood*, **2016**, 128, 3892-3892	2.2	2
66	Analysis of Outcomes of Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated in Randomized Clinical Trials. *Blood*, **2016**, 128, 4000-4000	2.2	1
65	Clonal Events of Aplastic Anemia Related to the Evolution to Myelodysplastic Syndrome. *Blood*, **2016**, 128, 4290-4290	2.2	1
64	A New Clinically-Based Subclassification Proposal in CMML with Significant Prognostic Implications to Overcome the MDS/MPN Categorizing Dilemma. *Blood*, **2016**, 128, 4320-4320	2.2	4
63	TP53 Mutations and Outcome in Patients with Myelodysplastic Syndromes (MDS). *Blood*, **2016**, 128, 4336-4336	2.2	7
62	Incorporation of Molecular Data into the Current Prognostic Models in Treated Patients with Myelodysplastic Syndromes: Which Model Is the Best. *Blood*, **2016**, 128, 50-50	2.2	5
61	A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML). *Blood*, **2016**, 128, 4065-4065	2.2	
60	Importance of Complete Remission on Predicting Overall Survival in Patients with Lower-Risk Myelodysplastic Syndromes (MDS). *Blood*, **2016**, 128, 4332-4332	2.2	1
59	Distinct Clinical and Biological Implications of Various DNTMT3A Mutations in Myeloid Neoplasms. *Blood*, **2016**, 128, 2872-2872	2.2	
58	BCOR and BCORL1 mutations in Myelodysplastic Syndromes (MDS): Clonal Architecture and Impact on Outcomes. *Blood*, **2016**, 128, 4293-4293	2.2	
57	Using Machine Intelligence Algorithms to Develop a Geno-Clinical Model to Predict Responses to Hypomethylating Agents in Myelodysplastic Syndromes. *Blood*, **2016**, 128, 3193-3193	2.2	
56	Landscape of Subclonal Mutations in Myelodysplastic Syndromes (MDS) Allows for a Novel Hierarchy of Clonal Advantage By Combining Germline and Somatic Mutations. *Blood*, **2016**, 128, 957-957	2.2	
55	Molecular landscape in acute myeloid leukemia: where do we stand in 2016. *Cancer Biology and Medicine*, **2016**, 13, 474-482	5.2	8
54	Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). *American Journal of Hematology*, **2016**, 91, 227-32	7.1	29

53	Chronic myelomoncytic leukemia: Are we finally solving the identity crisis?. *Blood Reviews*, **2016**, 30, 381-8	11.1	3
52	Improving Prognostic Modeling in Myelodysplastic Syndromes. *Current Hematologic Malignancy Reports*, **2016**, 11, 395-401	4.4	3
51	Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?. *Oncologist*, **2015**, 20, 1069-76	5.7	18
50	Chronic myelomonocytic leukemia: Forefront of the field in 2015. *Critical Reviews in Oncology/Hematology*, **2015**, 95, 222-42	7	19
49	The Revised International Prognostic Scoring System (IPSS-R) is not predictive of survival in patients with secondary myelodysplastic syndromes. *Leukemia and Lymphoma*, **2015**, 56, 3437-9	1.9	19
48	hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies. *Cancer Cell*, **2015**, 28, 486-499	24.3	88
47	Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes. *Haematologica*, **2015**, 100, e434-7	6.6	18
46	Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. *American Journal of Hematology*, **2015**, 90, 276-81	7.1	114
45	Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications. *Oncologist*, **2015**, 20, 1154-60	5.7	11
44	PHF6 - Somatic Mutations and Their Role in Pathophysiology of MDS and AML. *Blood*, **2015**, 126, 1259-1259	2.2	1
43	Outcome of Newly Diagnosed Acute Myeloid Leukemia (AML) Refractory to 1 or 2 Cycles of Induction Chemotherapy. *Blood*, **2015**, 126, 1319-1319	2.2	2
42	TET 2 Alterations in Myeloid Malignancies, Impact on Clinical Characteristics, Outcome, and Disease Predisposition. *Blood*, **2015**, 126, 1645-1645	2.2	1
41	Impact of Eltrombopag on Expansion of Clones with Somatic Mutations in Refractory Aplastic Anemia. *Blood*, **2015**, 126, 300-300	2.2	1
40	The Revised International Prognostic Scoring System "Molecular" (IPSS-Rm), a Validated and Dynamic Model in Treated Patients with Myelodysplastic Syndromes (MDS). *Blood*, **2015**, 126, 607-607	2.2	3
39	Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. *Blood*, **2015**, 126, 907-907	2.2	73
38	APC mutations in myeloid malignancies: Incidence and impact on leukemogenesis.. *Journal of Clinical Oncology*, **2015**, 33, 11047-11047	2.2	1
37	Impact of STAT3 Mutations on Clinical Features and Treatment Outcomes in Large Granular Lymphocyte Leukemia. *Blood*, **2015**, 126, 2216-2216	2.2	
36	hnRNP K Is a Novel Haploinsufficient Tumor Suppressor at the 9q21.32 Locus That Defines a Subset of AML. *Blood*, **2015**, 126, 439-439	2.2	

35	Network-Based Analysis of Exome Sequencing Mutations Identifies Molecular Subtypes of Myelodysplastic Syndromes. *Blood*, **2015**, 126, 611-611	2.2	
34	Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. *Leukemia and Lymphoma*, **2014**, 55, 1337-44	1.9	27
33	Paroxysmal nocturnal hemoglobinuria is not a cause of anemia in patients with myelofibrosis. *Leukemia and Lymphoma*, **2014**, 55, 2215-6	1.9	5
32	Acute myeloid leukemia in the elderly: do we know who should be treated and how?. *Leukemia and Lymphoma*, **2014**, 55, 979-87	1.9	29
31	Outcomes of Patients with Myelodysplastic Syndromes (MDS) Who Achieve Stable Disease after Treatment with Hypomethylating Agents (HMA). *Blood*, **2014**, 124, 3273-3273	2.2	3
30	An International Data Set for the Study of Chronic Myelomonocytic Leukemia (CMML) Validates Modern Prognostic Scoring Systems and Demonstrates a Critical Need for Novel Prognostication Strategies. *Blood*, **2014**, 124, 530-530	2.2	1
29	Bortezomib + MEC (Mitoxantrone, Etoposide, Cytarabine) for Relapsed/ Refractory Acute Myeloid Leukemia: Final Results of an Expanded Phase 1 Trial. *Blood*, **2014**, 124, 978-978	2.2	3
28	Different Genomic Patterns in Patients with Primary Acute Myeloid Leukemia (AML) Compared to Secondary AML in Patients with Normal Karyotype. *Blood*, **2014**, 124, 1054-1054	2.2	
27	Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia. *Expert Opinion on Pharmacotherapy*, **2013**, 14, 1977-86	4	7
26	Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≥60 years with newly diagnosed acute myeloid leukemia. *American Journal of Hematology*, **2013**, 88, 961-6	7.1	39
25	Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis. *Leukemia and Lymphoma*, **2013**, 54, 2537-9	1.9	16
24	The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia. *Frontiers in Oncology*, **2013**, 3, 218	5.3	19
23	The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia. *Haematologica*, **2013**, 98, e131	6.6	7
22	Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. *Blood*, **2013**, 121, 4655-62	2.2	296
21	Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. *Blood*, **2013**, 121, 4867-74	2.2	110
20	Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. *Haematologica*, **2013**, 98, 1686-8	6.6	22
19	Clofarabine Plus Low-Dose Cytarabine For The Treatment Of Patients Withhigher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing After, Or Are Refractory To, Hypomethylator Agent Therapy. *Blood*, **2013**, 122, 1525-1525	2.2	1
18	hnRNP K: A Novel Regulator of Hematopoiesis and A Potential Predictive Biomarker In Acute Myeloid Leukemia. *Blood*, **2013**, 122, 226-226	2.2	1

17	Early Results Of a Phase I/II Trial Of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) For Patients (Pts) With Acute Myeloid Leukemia and Myelodysplastic Syndrome. *Blood*, **2013**, 122, 3949-3949	2.2	1
16	Clofarabine Plus Low-Dose Cytarabine Induction Followed By Clofarabine Plus Low-Dose Cytarabine Alternating With Decitabine Consolidation In Acute Myeloid Leukemia Frontline Therapy For Older Patients. *Blood*, **2013**, 122, 3948-3948	2.2	
15	Outcome Of Patients With Myelodysplastic Syndrome (MDS) With Bone Marrow Blasts Between 10-30% Treated With Hypomethylating Agents Versus Intensive Chemotherapy. *Blood*, **2013**, 122, 2788-2788	2.2	1
14	EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. *Blood*, **2012**, 119, 4524-6	2.2	49
13	Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. *Haematologica*, **2012**, 97, 1242-5	6.6	32
12	Addition of All-Trans Retinoic Acid (ATRA) to the Combination of Fludarabine, Cytarabine, Idarubicin, with or without GCSF in Older, Higher Risk Patients with AML and High-Risk MDS Does Not Improve the Outcome in Those with NPM1 Mutation.. *Blood*, **2012**, 120, 2616-2616	2.2	1
11	A Phase I/II Trial of Combination of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). *Blood*, **2012**, 120, 3587-3587	2.2	2
10	Early Molecular and Cytogenetic Responses Predicts for Significantly Longer Event Free Survival (EFS) and Overall Survival (OS) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) an Analysis of 4 Tyrosine Kinase Inhibitor (TKI) Modalities (standard	2.2	2
9	Disease Patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) That Have BCR-ABL Transcript Levels > 10% At 3 Month of Therapy with Tyrosine Kinase Inhibitors (TKIs). *Blood*, **2012**, 120, 3757-3757	2.2	
8	Biological and Clinical Features of Patients with Acute Myeloid Leukemia Bearing Trisomy 21. *Blood* , **2012**, 120, 1488-1488	2.2	
7	Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients . *Blood*, **2012**, 120, 43-43	2.2	
6	Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm. *Blood*, **2012**, 120, 3554-3554	2.2	
5	Fatigue in Chronic Myelogenous Leukemia Patients (pts) Treated with Tyrosine Kinase Inhibitors (TKI),. *Blood*, **2011**, 118, 3785-3785	2.2	3
4	Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients Younger Than 61 Years with Newly Diagnosed Acute Myeloid Leukemia (AML). *Blood*, **2011**, 118, 1550-1550	2.2	
3	Prognostic Implication of Chromosome 17 Abnormalities in the Context of Monosomal Karyotype (MK) in Patients with Acute Myeloid Leukemia (AML) and Complex Cytogenetics. *Blood*, **2011**, 118, 1495-1495	2.2	0
2	The Optimal Timing for Stem Cell Collection After Induction Therapy for Patients with Multiple Myeloma. *Blood*, **2010**, 116, 2252-2252	2.2	
1	Plerixafor and G-CSF Versus Cyclophosphamide and G-CSF for Stem Cell Mobilization in Patients with Multiple Myeloma.. *Blood*, **2009**, 114, 2146-2146	2.2	2